Phase II Study of Dovitinib for FGFR1 Amplified Squamous Non-small Cell Lung Cancer

Trial Profile

Phase II Study of Dovitinib for FGFR1 Amplified Squamous Non-small Cell Lung Cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Apr 2017

At a glance

  • Drugs Dovitinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Apr 2017 Results investigating predictive biomarkers of dovitinib in lung squamous cell carcinoma, published in the Annals of Oncology
    • 17 Jun 2016 Results published in the Cancer
    • 17 Jun 2016 Status changed from active, no longer recruiting to completed, as per the results published in the Cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top